Education
About Us
Working with TipRanks
Follow Us
Vistagen Therapeutics Inc. (VTGN)
:VTGN
Earnings Data
Report Date
Feb 12, 2026TBA (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-0.37Last Year’s EPS
-0.46Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and a strong financial position, with strategic additions to the leadership team and a diverse pipeline poised for future growth. However, there were challenges in site management within clinical trials and uncertainty regarding FDA voucher eligibility.Company Guidance
Completion of PALISADE-3 Phase III Trial
The last patient completed the randomized double-blind portion of the PALISADE-3 Phase III trial for fasedienol, with top line results expected by the end of the calendar year.
Strong Financial Position
As of September 30, 2025, Vistagen reported $77.2 million in cash, cash equivalents, and marketable securities, covering all known aspects of the ongoing U.S. registration-directed PALISADE program.
Expansion of Leadership Team
Paul Edick joined the Board of Directors, bringing decades of experience with FDA approvals and commercial launches.
Diverse Pipeline and Upcoming Milestones
Vistagen is on track to release top line results from PALISADE-4 in the first half of 2026 and is advancing its pherine pipeline with itruvone for major depressive disorder and PH80 for menopausal hot flashes.
VTGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VTGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $3.80 | $3.80 | 0.00% |
Aug 07, 2025 | $2.73 | $2.97 | +8.79% |
Jun 17, 2025 | $2.38 | $2.06 | -13.45% |
Feb 13, 2025 | $2.85 | $2.97 | +4.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vistagen Therapeutics Inc. (VTGN) report earnings?
Vistagen Therapeutics Inc. (VTGN) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
What is Vistagen Therapeutics Inc. (VTGN) earnings time?
Vistagen Therapeutics Inc. (VTGN) earnings time is at Feb 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTGN EPS forecast?
VTGN EPS forecast for the fiscal quarter 2026 (Q3) is -0.37.